{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intramuscularly+%28IM+injection%29&page=6",
    "query": {
      "intervention": "intramuscularly (IM injection)",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 204,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intramuscularly+%28IM+injection%29&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intramuscularly+%28IM+injection%29&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T15:14:47.866Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00398073",
      "title": "Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Intraocular Melanoma",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "mouse gp100 plasmid DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "The Dermal PowderMed® devices",
          "type": "DEVICE"
        },
        {
          "name": "intramuscularly (IM injection)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "1 Year to 120 Years"
      },
      "enrollment_count": 35,
      "start_date": "2006-10",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-16",
      "last_synced_at": "2026-10-14T15:14:47.866Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00398073"
    },
    {
      "nct_id": "NCT00861744",
      "title": "Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rubella",
        "Mumps",
        "Measles",
        "Measles-Mumps-Rubella Vaccine"
      ],
      "interventions": [
        {
          "name": "GSK Biological's investigational vaccine 209762",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-R® II (Merck and Co)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varivax®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "12 Months to 15 Months"
      },
      "enrollment_count": 1259,
      "start_date": "2009-06-03",
      "completion_date": "2012-06-18",
      "has_results": true,
      "last_update_posted_date": "2020-01-03",
      "last_synced_at": "2026-10-14T15:14:47.866Z",
      "location_count": 45,
      "location_summary": "Tuscaloosa, Alabama • Conway, Arkansas • Jonesboro, Arkansas + 42 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Conway",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00861744"
    },
    {
      "nct_id": "NCT02296541",
      "title": "Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DNA Nat-B env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DNA CON-S env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DNA Mosaic env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-CMDR",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA Nat-B env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA CON-S env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA Mosaic env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for MVA-CMDR",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 105,
      "start_date": "2014-12",
      "completion_date": "2020-07-06",
      "has_results": false,
      "last_update_posted_date": "2023-04-24",
      "last_synced_at": "2026-10-14T15:14:47.866Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02296541"
    },
    {
      "nct_id": "NCT00955006",
      "title": "Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VRC-HIVDNA-016-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRCHIVADV014-00-VP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 17,
      "start_date": "2011-05",
      "completion_date": "2017-11-22",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-10-14T15:14:47.866Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00955006"
    },
    {
      "nct_id": "NCT01310413",
      "title": "Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza",
        "Influenza Vaccines"
      ],
      "interventions": [
        {
          "name": "Influenza A (H5N1) Virus monovalent vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 842,
      "start_date": "2011-03-07",
      "completion_date": "2014-01-26",
      "has_results": true,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-14T15:14:47.866Z",
      "location_count": 11,
      "location_summary": "Paramount, California • Sacramento, California • Newton, Kansas + 8 more",
      "locations": [
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Newton",
          "state": "Kansas"
        },
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01310413"
    },
    {
      "nct_id": "NCT03260790",
      "title": "Pneumococcal Vaccines in Patients With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "PCV13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PPSV23",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "19 Years to 64 Years"
      },
      "enrollment_count": 17,
      "start_date": "2017-10-01",
      "completion_date": "2020-12-25",
      "has_results": true,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-10-14T15:14:47.866Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03260790"
    },
    {
      "nct_id": "NCT04518410",
      "title": "ACTIV-2: A Study for Outpatients With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus",
        "Covid19"
      ],
      "interventions": [
        {
          "name": "bamlanivimab 7000mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BRII-196+BRII-198",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 (IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 (IM)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SNG001",
          "type": "DRUG"
        },
        {
          "name": "Camostat",
          "type": "DRUG"
        },
        {
          "name": "BMS-986414 + BMS-986413",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SAB-185 (3,840 Units/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SAB-185 (10,240 Units/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CASIRIVIMAB + IMDEVIMAB",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Bamlanivimab 7000mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Bamlanivimab 700mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BRII-196+BRII-198",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SNG001",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Camostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SAB-185 (low dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BMS-986414 + BMS-986413",
          "type": "DRUG"
        },
        {
          "name": "Placebo for AZD7442 (IV)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for AZD7442 (IM)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SAB-185 (high dose)",
          "type": "DRUG"
        },
        {
          "name": "bamlanivimab 700mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4044,
      "start_date": "2020-08-19",
      "completion_date": "2023-06-20",
      "has_results": true,
      "last_update_posted_date": "2024-08-02",
      "last_synced_at": "2026-10-14T15:14:47.866Z",
      "location_count": 207,
      "location_summary": "Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04518410"
    },
    {
      "nct_id": "NCT03185013",
      "title": "REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cervical Dysplasia",
        "Cervical High Grade Squamous Intraepithelial Lesion",
        "HSIL"
      ],
      "interventions": [
        {
          "name": "VGX-3100",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Electroporation (EP)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 201,
      "start_date": "2017-06-28",
      "completion_date": "2021-04-06",
      "has_results": true,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-10-14T15:14:47.866Z",
      "location_count": 22,
      "location_summary": "Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Lake Worth",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03185013"
    },
    {
      "nct_id": "NCT03814590",
      "title": "A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV Vaccine (GSK3844766A) unadjuvanted low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) unadjuvanted medium dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) unadjuvanted high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Saline solution)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1053,
      "start_date": "2019-01-21",
      "completion_date": "2020-11-30",
      "has_results": true,
      "last_update_posted_date": "2022-08-05",
      "last_synced_at": "2026-10-14T15:14:47.866Z",
      "location_count": 18,
      "location_summary": "Jacksonville, Florida • Miami, Florida • Stockbridge, Georgia + 15 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03814590"
    },
    {
      "nct_id": "NCT07047716",
      "title": "Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Pre-exposure Prophylaxis"
      ],
      "interventions": [
        {
          "name": "Lenacapavir Injection",
          "type": "DRUG"
        },
        {
          "name": "Lenacapavir Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 339,
      "start_date": "2025-07-22",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-14T15:14:47.866Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07047716"
    }
  ]
}